Tagged with China

Hong Kong The GBA Healthcare Group aims to provide accessible, affordable, and accountable healthcare in the Greater Bay Area through a public-private partnership model, focusing on primary healthcare and health insurance empowerment. Co-CEO Dr Felix Lee, who also serves as Head of Healthcare Investments at parent group Chow Tai Fook Enterprises Limited,…

Hong Kong Former Hong Kong SAR Chief Executive CY Leung  discusses Hong Kong’s unique positioning within the Greater Bay Area and the importance of its openness, international business mindset, and strong sense of social responsibility in maintaining its global relevance. Leung also reflects on Hong Kong’s response to political and economic uncertainties…

Hong Kong We sat down with Lawrence Wong, general manager of the Swiss company’s Hong Kong affiliate, to discuss Ferring’s recent milestones, such as moving into new areas like uro-oncology and the microbiome space. Wong also spoke about the recent “1+” regulatory reform, Hong Kong’s strategic position in the Greater Bay Area,…

Hong Kong Ronald Lo, general manager of Roche Diagnostics Hong Kong shares some of company’s advances in diagnostic disease prevention that are particularly revelant in Hong Kong, such as its recently FDA-approved HPV self-sampling in a territory where only 52 percent of women have ever done cervical screening, and in light of…

Hong Kong Derek Chang introduces some of the key therapeutic advancements Novartis has been able to introduce in Hong Kong, including cell therapy and siRNA therapies, and its ongoing focus on targeted radioligand therapies, which benefit from the territory’s robust legislative framework. Chang also touches on the importance of Hong Kong’s “1+”…

Hong Kong Yuko Mizuma, general manager of Hong Kong and Macau at Eli Lilly Asia, Inc., shares her impressions of Hong Kong’s healthcare ecosystem after working in Japan and the US, discusses the local impact of obesity, which affects 33 percent of the population, and the positive reimbursement outlook for newer treatments…

Hong Kong Drawing on an extensive management background in telecom, IT, and digital, Vincent Ma now serves as CEO of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP). He outlines the under-construction tech park’s unique positioning, linking Hong Kong’s jurisdiction with mainland China’s resources, and HSITP’s plans to attract both Chinese and…

Hong Kong Johnson & Johnson Innovative Medicine veteran and general manager of the company’s Hong Kong & Macau affiliate SunKeun Huh explains J&J Hong Kong’s strong position in schizophrenia and its significant oncology milestones, comments on the affiliate’s push to enhance clinical trials in alignment with mainland China, local talent development and the…

China Despite an adverse funding panorama and looming geopolitical tensions, Chinese biotech is still thriving. Companies originating in China are advancing promising pipelines, going public, looking beyond China’s borders with a record 63 cross-region out-licensing deals in 2023, and attracting the attention of global pharma. Recent PharmaBoardroom interviewees weigh in on…

China CanSinoBIO was established to create high-quality, affordable vaccines for developing countries, addressing global health disparities. Having already developed an inhalable COVID-19 vaccine, the Chinese firm is now working on new TB and polio vaccines using advanced technologies. CEO and Chairman Yu Xuefeng outlines CanSino’s approach to IP protection and sharing,…

Hong Kong A surgeon by training, Prof Philip Chiu is now dean of the Faculty of Medicine at the research-focused Chinese University of Hong Kong (CUHK). He shares the creation of CUHK’s Multiscale Medical Robotics Centre and the robotic system for minimally invasive surgery developed there; CUHK’s focus on translational medicine and…

China Writing in the July 2024 edition of DIA’s Global Forum magazine Mingcan DU and Fengyun (Vicky) HAN of Johnson & Johnson Global Regulatory Policy and Intelligence look back at the evolution of the use of real-world evidence (RWE) in regulatory decision-making in China, including key use cases and future prospects.…